



Please type plus sign (+) inside this box →



PTO/SB/21 (08-00)
Approved for use through 10/31/2003 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/918,601	
	Filing Date	July 30, 2001	
	First Named Inventor	NOLAN, GARRY P.	
	Group Art Unit	1627	
	Examiner Name	WESSENDORF, TERESA D.	
Total Number of Pages in This Submission	8	Attorney Docket Number	RIGL-004CON3

ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Form PTO/SB/08A 2. Postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36,677 BOZICEVIC, FIELD & FRANCIS LLP
Signature	
Date	March 21, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: March 21, 2003.			
Typed or printed name	Susan M. Alessi		
Signature		Date	March 21, 2003


Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



FREE TRANSMITTAL for FY 2003		Complete if Known	
Effective 01/01/2003. Patent fees are subject to annual revision.		Application Number	09/918,601
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Filing Date	July 30, 2001
TOTAL AMOUNT OF PAYMENT (\$)		First Named Inventor	NOLAN, GARRY
(\$)		Examiner Name	WESSENDORF, TERESA
METHOD OF PAYMENT (check all that apply)		Art Unit	1627
<input type="checkbox"/> Check <input type="checkbox"/> Credit Card <input type="checkbox"/> Money Order <input type="checkbox"/> Other <input type="checkbox"/> None		Attorney Docket No.	RIGL-004CON3
<input checked="" type="checkbox"/> Deposit Account:		FEE CALCULATION (continued)	
Deposit Account Number 50-0815		3. ADDITIONAL FEES	
Deposit Account Name Bozicevic, Field & Francis LLP		Large Entity Fee Fee Code (\$)	
The Commissioner authorized to: (check all that apply)		Small Entity Fee Fee Code (\$)	
<input checked="" type="checkbox"/> Charge fees indicated below <input checked="" type="checkbox"/> Credit any overpayments		Fee Description	
<input type="checkbox"/> Charge any additional fee(s) during the pendency of this application		Fee Paid	
<input type="checkbox"/> Charge fees indicated below, except for the filing fee to the above-identified deposit account.			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity Fee Fee Code (\$)			
Small Entity Fee Fee Code (\$)			
Fee Description			
Fee Paid			
1001 750 2001 375 Utility filing fee			
1002 330 2002 165 Design filing fee			
1003 520 2003 260 Plant filing fee			
1004 750 2004 375 Reissue filing fee			
1005 160 2005 80 Provisional filing fee			
SUBTOTAL (1)			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			
Extra Claims Fee from below Fee Paid			
Total Claims -20** = x =			
Indep. Claims -3** = x =			
Multiple Dependent =			
Large Entity Fee Fee Code (\$)			
Small Entity Fee Fee Code (\$)			
Fee Description			
Fee Paid			
1202 18 2202 9 Claims in excess of 20			
1201 84 2201 42 Independent claims in excess of 3			
1203 280 2203 140 Multiple dependent claim, if not paid			
1204 84 2204 42 ** Reissue independent claims over original patent			
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent			
SUBTOTAL (2) \$			
**or number previously paid, if greater; For Reissues, see above.			
SUBMITTED BY		Complete (if applicable)	
Name (Print/Type) Pamela J. Sherwood		Registration No. (Attorney/Agent) 36,677	
Signature <i>Pamela Sherwood</i>		Telephone (650) 327-3400	
		Date 03/21/2003	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231 on this date.

Typed or Printed Name	Susan M. Alessi		
Signature	<i>Susan M. Alessi</i>	Date	March 21, 2003
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	Attorney Docket	RIGL-004CON3	
	First Named Inventor	NOLAN, GARRY	
	Application Number	09/918,601	
	Filing Date	July 30, 2001	
	Group Art Unit	1627	
	Examiner Name	WESSENDORF, TERESA D.	
Address to: Commissioner for Patents Washington, D.C. 20231		Title: "METHODS FOR SCREENING FOR TRANSDOMINANT INTRACELLULAR EFFECTOR PEPTIDES AND RNA MOLECULES"	

RECEIVED
APR 02 2003
TECH CENTER 1600/2900

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application or *after* the mailing date of the first Office Action on the merits, whichever event occurred last, but *before* the mailing date of either a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.

A Form PTO-SB/08A listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

- ☐ All of the references identified herein are being submitted prior to the final determination on patentability by the Office.
- ☐ All of the references identified herein were cited in an International (PCT) Search Report dated *, in a PCT application corresponding to the above-identified U.S. application. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is enclosed herewith. Copies of the references are submitted herewith.
- ☒ All of the references identified herein were disclosed in parent application Serial No. 09/727,715 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d), except if noted below.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


04/01/2003 EAREGAY1 00000022 500815 09918601

01 FC:1806 180.00 CH


X Please charge the \$180.00 fee required by 37 C.F.R. §1.97(c) and set forth in 37 C.F.R. 1.17(p) and any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to Deposit Account No. 50-0815, order number RIGL-004CON3.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 21, 2003

By: 
Pamela J. Sherwood
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/918,601	
			Filing Date	July 30, 2001	
			First Named Inventor	NOLAN, GARRY P.	
			Art Unit	1627	
Examiner Name	WESSENDORF, TERESA D.				
Attorney Docket Number	RIGL-004CON3				
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		4.618.578		10-1986	Burke <i>et al.</i>	RECEIVED APR 02 2003 TECH CENTER 1600/2900
		5.650.489		07-1997	Lam <i>et al.</i>	
		5.698.396		12-1997	Pfreundschuh <i>et al.</i>	
		5.747.334		05-1998	Kav <i>et al.</i>	
		5.763.192		06-1998	Kauffman <i>et al.</i>	
		5.770.434		06-1998	Huse	
		5.814.476		09-1998	Kauffman <i>et al.</i>	
		5.817.483		10-1998	Kauffman <i>et al.</i>	
		5.824.514		10-1998	Kauffman <i>et al.</i>	
		5.840.479		11-1998	Little <i>et al.</i>	
		5.935.823		08-1999	Fowlkes <i>et al.</i>	
		5.955.275		09-1999	Kamb <i>et al.</i>	
		6.153.380		11-2000	Nolan <i>et al.</i>	
		6.194.544		02-2001	Huffman <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 0 440 146 A2	01-1991	Little <i>et al.</i>		
		EP 0 557 897 A1	09-1993	Dillon <i>et al.</i>		
		WO 93/03143 A1	02-1993	Anderson <i>et al.</i>		
		WO 94/18219 A1	08-1994	Barbas <i>et al.</i>		
		WO 94/20608 A1	09-1994	Hodgeson		
		WO 94/29469 A2	12-1994	Nabel <i>et al.</i>		
		WO 95/11998 A1	05-1995	Wang <i>et al.</i>		

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/918.601
Sheet	2	Filing Date	July 30, 2001
	of	First Named Inventor	NOLAN, GARRY P.
	3	Art Unit	1872
		Examiner Name	WESSENDORF, TERESA D.
		Attorney Docket Number	RIGL-004-0093
OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ATCC catalog Internet printout regarding Cell Line HB-101 (2001)	
		CWIRLA, S. <i>et al.</i> , "Peptides on Phage: A vast library of peptides for identifying ligands" PROC. NATL. ACAD. SCI. USA, Vol. 87, August 1990, pp. 6378-6382.	
		DUBE <i>et al.</i> , "Selection of new biologically active molecules from random nucleotide sequences." Gene Vol. 137, Aug 1993, pp. 41-47.	
		DUEÑAS, M. <i>et al.</i> , "Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage and Phage Replication", BIO/TECHNOLOGY, Vol. 12, Oct. 1994, pp. 999-1002.	
		FURKA, A. <i>et al.</i> , "General method for rapid synthesis of multi-component peptide mixtures", INT. J. PEPTIDE PROTEIN RES., 37, 1991 pp. 487-493.	
		GISSEL, B. <i>et al.</i> , "Identification of Avidin and Streptavidin Binding Motifs Among Peptides Selected from a Synthetic Peptide Library Consisting solely of D-Amino Acids", JOURNAL OF PEPTIDE SCIENCE, Vol. 1, 1995, pp. 217-226.	
		HOUGHTEN, R. <i>et al.</i> , "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery" NATURE, Vol. 354, 7 Nov. 1991, pp. 84-86.	
		KARTTUNEN <i>et al.</i> , Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens. PROC. NATL. ACAD. SCI. USA, Vol. 89, 1992, pp. 6020-6024.	
		KAUFFMAN, S. <i>et al.</i> , "The NK Model of Rugged Fitness Landscapes And Its Application to Maturation of the Immune Response" J. THEOR. BIOL., Vol. 141(2), 1989, pp. 211-245.	
		KAUFFMAN, S. <i>et al.</i> , "Toward a General Theory of Adaptive Walks on Rugged Landscapes", J. THEOR. BIOL. Vol 128(1), 1987, pp. 11-45.	
		LAM, K. <i>et al.</i> , "A new type of synthetic peptide library for identifying ligand-binding activity", NATURE Vol. 354, 7 Nov. 1991, pp. 82-84.	
		LONG, E. <i>et al.</i> , "Invariant Chain Prevents the HLA-DR Restricted Presentation of a Cytosolic Peptide", THE JOURNAL OF IMMUNOLOGY, 153, 1994, pp. 1487-1494.	
		LUND, A. <i>et al.</i> , "Increased cloning efficiency by temperature cycle ligation", NUCLEIC ACIDS RESEARCH, Vol. 24, No. 4, 1996, pp 800-801.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/918,601
		Filing Date	July 30, 2001
		First Named Inventor	NOLAN, GARRY P.
		Art Unit	1627
		Examiner Name	WESSENDORF, PRESA D.
Sheet	3 of 3	Attorney Docket Number	RIGL-004CON3
	MALNATI, M. <i>et al.</i> , "Processing pathways for presentation of cytosolic antigen to MHC class II-restricted cells", NATURE Vol. 357, 25 June 1992, pp. 702-704.		
	MILLER, A.D. <i>et al.</i> , "Improved Retroviral Vectors for Gene Transfer and Expression", BioTechniques, Vol. 7, No. 9, 1989, pp. 980-990.		
	MURPHY, A. <i>et al.</i> , "p1zd39: A new type of cDNA expression vector for low background, high efficiency directional cloning", NUCLEIC ACIDS RESEARCH, Vol. 19, No. 12, (1991), pp. 3403-3408.		
	ROITT <i>et al.</i> , "Kurzes Lehrbuch der Immunologie, 2. Auflage, p. 86, (1991)		
	ROMPP <i>et al.</i> , "Bd. 5 P1-S-1995, Georg Thieme Verlag Stuttgart, p. 3543 (in German)		
	SCHUMACHER, T <i>et al.</i> , "Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules", EUR. J. IMMUNOL. (Germany), Vol. 22 (6), June 1992, pp. 1405-12.		
	SCOTT, J., "Discovering peptide ligands using epitope libraries", TIBS 17, (1992), pp. 241-245.		
	SEED, B. <i>et al.</i> , "Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure", PROC. NATL. ACAD. SCI. USA, Vol. 84, May 1987, pp. 3365-3369.		
	STRYER <i>et al.</i> , "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 53-57 (in German)(published in America in Stryer, (1998), L. Biochemistry 3 rd Ed., New York: W.H. Freeman and Company, pp. 50-55		
	STRYER <i>et al.</i> , "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 124-126 (in German)(published in America in Stryer, (1998), L. Biochemistry 3 rd Ed., New York: W.H. Freeman and Company, pp. 120-123		
	STRYER <i>et al.</i> , "Biochemie, Heidelberg, Berlin: Spektrum-Verlag, (1994), pp. 807-808 (in German)(published in America in Stryer, (1988), L. Biochemistry 3 rd Ed., New York: W.H. Freeman and Company, pp. 773-775		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.